Horan Securities’s Vertex Pharmaceuticals VRTX Stock Holding History

Horan Securities’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-9	Closed	-$3.17K	–	656
2023 Q2	$3.17K	Hold	9	–	–	﹤0.01%	525
2023 Q1	$2.84K	Hold	9	–	–	﹤0.01%	528
2022 Q4	$2.6K	Hold	9	–	–	﹤0.01%	533
2022 Q3	$3K	Hold	9	–	–	﹤0.01%	460
2022 Q2	$3K	Hold	9	–	–	﹤0.01%	513
2022 Q1	$2K	Hold	9	–	–	﹤0.01%	460
2021 Q4	$2K	Buy	+9	New	+$1.75K	﹤0.01%	463
2021 Q2	$2K	Hold	9	–	–	﹤0.01%	417
2021 Q1	$2K	Buy	+9	New	+$1.98K	﹤0.01%	377
2020 Q3	–	Sell	-23	Closed	-$7K	–	396
2020 Q2	$7K	Hold	23	–	–	0.01%	222
2020 Q1	$5K	Buy	+23	New	+$5.28K	0.01%	175

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Horan Securities's VRTX Position: Q3 2023 in Review

Horan Securities sold out of Vertex Pharmaceuticals (VRTX) in Q3 2023, closing a stake of 9 shares — an estimated $3.17K sold.

Horan Securities first reported a position in VRTX in Q1 2020 and held it in 11 quarters. The position peaked at $7K in Q2 2020. 1,277 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

Horan Securities reported no remaining Vertex Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Horan Securities sold 9 Vertex Pharmaceuticals shares in Q3 2023, an estimated $3.17K.
Horan Securities first reported a position in Vertex Pharmaceuticals in Q1 2020 and held it in 11 quarters.
Horan Securities's Vertex Pharmaceuticals position peaked at $7K in Q2 2020.
1,277 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on Horan Securities's 13F filing for Q3 2023, filed 1 Nov 2023.